MDxHealth SA (NASDAQ:MDXH) Sees Significant Increase in Short Interest

MDxHealth SA (NASDAQ:MDXH) was the target of a significant growth in short interest in the month of December. As of December 31st, there was short interest totaling 39,441 shares, a growth of 162.5% from the December 15th total of 15,027 shares. Based on an average trading volume of 115,122 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.1% of the company’s shares are sold short. Currently, 0.1% of the company’s shares are sold short. Based on an average trading volume of 115,122 shares, the days-to-cover ratio is presently 0.3 days.

MDxHealth Price Performance

NASDAQ MDXH opened at $3.61 on Wednesday. The stock’s 50-day moving average is $3.56 and its 200-day moving average is $3.49. MDxHealth has a one year low of $1.35 and a one year high of $5.33. The firm has a market cap of $170.72 million, a P/E ratio of -5.64 and a beta of 1.62.

MDxHealth (NASDAQ:MDXH) last announced its earnings results on Wednesday, November 12th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.04). The company had revenue of $27.43 million for the quarter, compared to analyst estimates of $24.11 million. MDxHealth had a negative return on equity of 1,078.01% and a negative net margin of 30.50%. Equities analysts anticipate that MDxHealth will post -1.15 EPS for the current year.

Institutional Trading of MDxHealth

Several hedge funds and other institutional investors have recently modified their holdings of MDXH. FreeGulliver LLC acquired a new position in shares of MDxHealth during the second quarter worth about $273,000. Calamos Advisors LLC bought a new stake in MDxHealth in the 3rd quarter valued at approximately $305,000. GSA Capital Partners LLP acquired a new position in MDxHealth during the 3rd quarter worth approximately $48,000. Jefferies Financial Group Inc. bought a new position in shares of MDxHealth during the 3rd quarter worth approximately $53,000. Finally, Russell Investments Group Ltd. acquired a new stake in shares of MDxHealth in the third quarter valued at approximately $461,000.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on MDXH. TD Cowen boosted their price objective on MDxHealth from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Lake Street Capital boosted their price target on shares of MDxHealth from $7.00 to $9.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. BTIG Research restated a “buy” rating and issued a $7.00 price objective on shares of MDxHealth in a report on Tuesday, December 23rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MDxHealth in a report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $7.75.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.